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of poor solubility of eumelanin in alkali solution this method may 
lack the changes in eumelanin content but detect only the increased 
amount of pheomelanin. To include the eumelanin in the analytic 
approach, alkaline hydrogen peroxide oxidation was performed and 
degraded products were separated by HPLC.
In addition, the impact of cold atmospheric plasma on morphology 
and viability was minor. The pattern of melanosomal distribution re-
mained similar. In the least pigmented SK- Mel- 28 cells MiTF expres-
sion doubled after plasma treatment. In the other tested cell lines, 
plasma exposure revealed only minor effects on the expression of 
MiTF in our experimental setup.
Modulation of melanin by cold plasma can be a useful tool. However, 
further investigations are required to elucidate the underlying sign-
aling cascade.
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Background: Genitourinary Syndrome of Menopause (GSM) is a 
chronic and usually progressive skin disease which affects up to 50% 
of postmenopausal women. Symptoms, such as vaginal dryness, 
itching and burning have negative impacts on the women’s sexual 
activity and often come along with urinary problems. Furthermore, 
these consequences influence the women’s quality of life (QoL). 
Patient- reported outcome measures can be used to measure the im-
pact of GSM.
Objectives: We aimed to identify all existing PROMs that were de-
veloped and/or validated for measuring patient- reported outcomes 
in women with GSM or vulvovaginal symptoms during menopause 
and assess the quality of these PROMs in a transparent and struc-
tured way.
Methods: We performed a systematic literature search in MEDLINE, 
EMBASE, Web of Science and smaller data bases, and hand- searched 
reference lists of included studies. Only studies in English, German, 
French or Italian aiming at the evaluation of measurement proper-
ties, the development of a PROM, or the evaluation of the interpret-
ability of the PROMs of interest were eligible. The methodological 
quality of eligible studies was evaluated with the COnsensus- based 
Standards for the selection of health Measurement INstruments 
(COSMIN) risk of bias checklist. Quality criteria for good meas-
urement properties were applied and the quality of evidence was 
graded using a GRADE approach. Information on interpretability and 
feasibility was extracted as well. PROMs were then categorized into 
three categories. PROMs of category A had evidence for sufficient 
content validity and at least low quality evidence for sufficient in-
ternal consistency, PROMs of category C had high- quality evidence 
for an insufficient measurement property, and PROMs of category B 
could not be categorized in A or C.
Results: Eight studies, two of which were found by reference list 
screening, were included. These studies reported on four PROMs. 
All of the included PROMs showed sufficient content validity. Two 
of the PROMs, the Vaginal Symptoms Questionnaire (VSQ) and the 
Day- to- Day Impact of Vaginal Aging (DIVA) showed moderate- to- 
high quality of evidence for sufficient structural validity and inter-
nal consistency, and were categorized as A. They can be therefore 
recommended for future use. The UGAQoL still has the opportunity 
to be recommended for use, but further validation is needed. The 
overall rating was often indeterminate since structural validity or 
important reliability parameters were not reported. The Urogenital 
symptom scale cannot be recommended for use since there was high 
quality of evidence for insufficient structural validity and internal 
consistency.
Conclusion: Currently, two PROMs for women with GSM or vul-
vovaginal symptoms can be recommended. Nevertheless, those 
PROMs do not cover the urinary component of GSM. Future vali-
dation research should try to confirm and extend the measurement 
properties of those PROMs to strengthen this recommendation.
PROSPERO registration CRD42018092384.
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Background: The Childhood Atopic Dermatitis Impact Scale (CADIS) 
is an instrument to measure quality of life (QoL) in young children af-
fected by atopic dermatitis (AD) and their parents. It consists of five 
domains, “Symptoms”, “Activity Limitations and Behaviour”, “Family 
and Social Function”, “Sleep”, and “Emotions”.
Objectives: We aimed to evaluate the responsiveness (sensitivity to 
change in those whose condition had changed), smallest detectable 
change (SDC) and minimal important change (MIC) for the CADIS 
total score and each domain separately.
Methods: Parents and primary caregivers of 300 young children 
completed the CADIS and a global rating of their child’s skin condition 
at baseline and four- week follow- up. Kruskal- Wallis- tests, Wilcoxon- 
tests and effect sizes were used to assess responsiveness. The SDC 
